According to the International Foundation of Employee Benefit Plans, as of 2025: 55% of employers cover GLP-1 medications only for diabetes through their health plans, down from 57%in 2024 36% cover GLP-1 medications for both diabetes and weight loss through their health plans, up from 34%in 2024 Other sources report a much higher GLP-1 coverage for weight loss, between 49% and 57% among employers
Knowing what to expect and how to respond helps you manage your therapy effectively
Research on GLP-1 medications shows that gastrointestinal symptoms peak in weeks two through four of treatment, then typically improve
Higher-potency formulations (semaglutide up to 2.4 mg and tirzepatide) were used, which may account for stronger weight effects compared to pediatric trials that employed lower doses
And some work on the growth hormone axis to restore the body composition regulation that estrogen used to support
Nausea during Ozempic use usually means the dose is too high or you need slower titration